BSE Live
Mar 24, 15:40Prev. Close
1559.15
Open Price
1573.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 24, 15:40Prev. Close
1560.30
Open Price
1604.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Caplin Point Laboratories (in Rs. Cr.) | Jun 15 | Jun 14 | Jun 13 | Jun 12 | Jun 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 27.09 | 16.97 | 9.47 | 5.42 | 4.33 | |
| Diluted EPS (Rs.) | 27.09 | 16.97 | 9.47 | 5.42 | 4.33 | |
| Cash EPS (Rs.) | 32.57 | 19.24 | 10.43 | 6.18 | 5.83 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 59.50 | 38.75 | 26.58 | 20.04 | 16.94 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 61.97 | 41.22 | 29.05 | 22.51 | 19.42 | |
| Dividend / Share(Rs.) | 5.00 | 4.00 | 2.50 | 2.00 | 1.50 | |
| Revenue from Operations/Share (Rs.) | 158.99 | 110.12 | 81.19 | 71.22 | 54.95 | |
| PBDIT/Share (Rs.) | 39.25 | 24.45 | 15.40 | 8.52 | 7.70 | |
| PBIT/Share (Rs.) | 33.77 | 22.17 | 14.44 | 7.75 | 6.19 | |
| PBT/Share (Rs.) | 33.62 | 22.09 | 14.24 | 7.17 | 5.53 | |
| Net Profit/Share (Rs.) | 27.09 | 16.97 | 9.47 | 5.42 | 4.33 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 24.68 | 22.19 | 18.97 | 11.95 | 14.00 | |
| PBIT Margin (%) | 21.24 | 20.13 | 17.78 | 10.88 | 11.26 | |
| PBT Margin (%) | 21.14 | 20.05 | 17.54 | 10.06 | 10.05 | |
| Net Profit Margin (%) | 17.04 | 15.40 | 11.66 | 7.60 | 7.87 | |
| Return on Networth / Equity (%) | 45.53 | 43.78 | 35.62 | 27.03 | 25.52 | |
| Return on Capital Employed (%) | 39.35 | 35.28 | 27.23 | 21.37 | 20.97 | |
| Return on Assets (%) | 18.33 | 14.71 | 11.17 | 7.86 | 9.16 | |
| Total Debt/Equity (X) | 0.01 | 0.04 | 0.09 | 0.22 | 0.37 | |
| Asset Turnover Ratio (%) | 107.62 | 95.51 | 95.82 | 103.46 | 116.44 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.65 | 0.44 | 0.45 | 0.81 | 1.07 | |
| Quick Ratio (X) | 0.54 | 0.36 | 0.33 | 0.73 | 0.94 | |
| Inventory Turnover Ratio (X) | 18.98 | 21.32 | 13.75 | 19.16 | 16.09 | |
| Dividend Payout Ratio (NP) (%) | 18.45 | 23.57 | 26.40 | 36.92 | 34.67 | |
| Dividend Payout Ratio (CP) (%) | 15.35 | 20.78 | 23.96 | 32.35 | 25.71 | |
| Earnings Retention Ratio (%) | 81.55 | 76.43 | 73.60 | 63.08 | 65.33 | |
| Cash Earnings Retention Ratio (%) | 84.65 | 79.22 | 76.04 | 67.65 | 74.29 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1,365.46 | 313.44 | 61.07 | 18.13 | 21.74 | |
| EV/Net Operating Revenue (X) | 5.68 | 1.88 | 0.50 | 0.17 | 0.26 | |
| EV/EBITDA (X) | 23.02 | 8.49 | 2.62 | 1.41 | 1.87 | |
| MarketCap/Net Operating Revenue (X) | 5.85 | 2.01 | 0.58 | 0.36 | 0.41 | |
| Retention Ratios (%) | 81.54 | 76.42 | 73.59 | 63.07 | 65.32 | |
| Price/BV (X) | 15.63 | 5.71 | 1.77 | 1.29 | 1.32 | |
| Price/Net Operating Revenue | 5.85 | 2.01 | 0.58 | 0.36 | 0.41 | |
| Earnings Yield | 0.03 | 0.08 | 0.20 | 0.21 | 0.19 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
24.03.2026
24.03.2026
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth